Bangalore-based Biocon Ltd. (BSE code: 532523, NSE: BIOCON), a biopharmaceuticals major, reported a net profit of Rs.361 crore with Rs.1,000 crore as revenue for the fiscal year 2015-16.
The overall Sales at Rs 971 Cr registered a growth of 17% in Q4FY16. The Biopharmaceutical segment delivered sales of Rs 655 Cr, reporting a growth of 11% y-o-y. Within the segment, Biopharma grew 12% delivering Rs 554 Cr, while Branded Formulations reported a growth of 3% with sales at Rs 101 Cr for this quarter.
Biocon Chairperson and Managing Director, Kiran Mazumdar-Shaw said: “Biocon has closed the year with a landmark quarter, crossing a milestone Rs 1,000 Cr consolidated revenues for the first time. Syngene also closed FY16 on a strong note by crossing a Rs 1,000 Cr annual revenue mark."
Key developments this quarter as reported in the results include: